个人简介:
Dr. Patrick Y. Lu
Chairman of the Board, Executive Director, President & Chief Executive Officer
Dr. Patrick Y. Lu founded and has led Sirnaomics from an early discovery startup to a siRNA therapeutics product company, with multiple programs currently at the clinical stage. Dr. Lu brings 25+ years of nucleic acid drug development experience at Novartis, Digene, and Intradigm, where he was a co-founder. He has helped Sirnaomics raising over $270 million and develop the novel siRNA therapeutic, STP705, for the treatment of cancer and fibrosis diseases.
公司简介:
Sirnaomics is the first to achieve positive Phase IIb clinical outcomes in oncology clinical-stage RNA therapeutics biopharmaceutical company with a strong presence in both Asia and the U.S. that is discovering and developing innovative drugs for indications with significant unmet medical needs and large market opportunities. We have built a professional international team for the discovery and development of RNAi therapeutics and mRNA vaccines and therapeutics, based on our proprietary drug delivery technology platforms.